Short-term Low-Dose mTORC1 Inhibition in Aged Rats Counter-Regulates Age-Related Gene Changes and Blocks Age-Related Kidney Pathology
Open accessThe DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Rapalogs, inhibitors of mTORC1 (mammalian target of rapamycin complex 1), increase life span and delay age-related phenotypes in many species. However, the molecular mechanisms have not been fully elucidated. We determined gene expression changes comparing 6- and 24-month-old rats in the kidney, liver, and skeletal muscle, and asked which of these changes were counter-regulated by a clinically-translatable (short-term and low-concentration) treatment, with a rapalog (RAD001). Surprisingly, RAD001 had a more pronounced effect on the kidney under this regimen in comparison to the liver or skeletal muscle. Histologic evaluation of kidneys revealed that the severity of chronic progressive nephropathy lesions was lower in kidneys from 24-month-old rats treated with RAD001 compared with vehicle. In addition to other gene expression changes, c-Myc, which has been shown to regulate aging, was induced by aging in the kidney and counter-regulated by RAD001. RAD001 caused a decrease in c-Myc protein, which could be rescued by a proteasome inhibitor. These findings point to settings for use of mTORC1 inhibitors to treat age-related disorders, and highlight c-Myc regulation as one of the potential mechanisms by which mTORC1 inhibition is perturbing age-related phenotypes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. Genes up- and down-regulated by aging from 6 months to 24 months in rat kidney, liver, and gastrocnemius muscle, and the impact of RAD001 on the expression of these age-perturbed genes at 24 months. Rats aged 4.5 month and 22.5 months were treated with vehicle and rats aged 22.5 months were treated with RAD001 for 6 weeks, with a read-out at 6 and 24 months. Transcriptional profiling in the kidney, liver and gastrocnemius muscle was carried out by RNA-seq. Heat maps (A, B, C) depict genes that are differentially expressed between 6- and 24 month-old tissues (p < .05 adjusted for false discovery rate [FDR]) and the impact of RAD001 on the expression profile of these age-regulated genes. The blue hash (#) indicates genes that are significantly different between 6- and 24-month-old vehicle treated rats (p < .05 adjusted for FDR) and the red asterisk (*) indicates genes that are significantly different between 24-month-old vehicle treated and 24-month-old RAD001 treated rats (p < .05 adjusted for FDR). Standardized expression levels, from low to high, are colored from green to red: thus gene up-regulation is shown by a transition from green to red, and down regulation by a transition from red to green. In each heat map image, each column represents a single rat and each row represents a single gene. N = 8–10 rats per group.](https://figures.cochat.ai/paper-figures/fbaad61be8cc4c208fc1097329a99cf3/short-term-low-dose-mtorc1-inhibition-in-aged-rats-counter-regulates-age-related-figure-1.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another study demonstrated that short-term inhibition of mTORC1 with a low dose of everolimus in 24-month-old rats dramatically reduced age-related kidney disease and even counter-regulated age-related gene expression changes in the kidney185.”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [185]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Chronic Inflammation (Inflammaging) and Its Potential Contribution to Age-Associated Diseases
Franceschi, C., & Campisi, J. (2014) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glu057 · Cited by 3,891 · cited 1×
“There are many studies that demonstrate inflammatory signaling increases with age (8,30,31), and this was seen in the kidney in the current study.”
BackgroundRapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766 · cited 2×
“Inhibition of the mammalian target of rapamycin (mTORC1) pathway is perhaps the best-validated pharmacological intervention to forestall agerelated phenotypic changes; inhibition of mTORC1 using rapamycin can extend murine life span, including in settings where the treatment is initiated relatively late in life (9,10,…”
BackgroundKenyon, C. J. (2010) · Nature · doi:10.1038/nature08980 · Cited by 2,739 · cited 1×
“Quite a few other mechanisms have been put forth as potentially regulating age-related conditions, and life span (16).”
BackgroundAgeing as a Risk Factor for Disease
Niccoli, T., & Partridge, L. (2012) · Current Biology · doi:10.1016/j.cub.2012.07.024 · Cited by 1,831
The Laboratory Rat: Relating Its Age With Human's.
(2013) · Europe PMC (PubMed Central) · Cited by 1,705
mTOR is a key modulator of ageing and age-related disease
Johnson, S. C., Rabinovitch, P. S., & Kaeberlein, M. (2013) · Nature · doi:10.1038/nature11861 · Cited by 1,676
Autophagy maintains stemness by preventing senescence
García-Prat, L., Martínez-Vicente, M., Perdiguero, E., Ortet, L., Rodríguez-Ubreva, J., Rebollo, E., Ruiz-Bonilla, V., Gutarra, S., Ballestar, E., Serrano, A. L., et al. (2016) · Nature · doi:10.1038/nature16187 · Cited by 1,355 · cited 1×
“As to mechanism, treatment with rapamycin has been shown to reverse signs of senescence in stem cells (7,13,14) and decrease inflammation (8,15).”
BackgroundIn Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming.
Ocampo, A., Reddy, P., Martinez-Redondo, P., Platero-Luengo, A., Hatanaka, F., Hishida, T., Li, M., Lam, D., Kurita, M., Beyret, E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.052 · Cited by 988 · cited 1×
“A distinct study very recently demonstrated that transient upregulation of the Yamanaka factors, the four genes which are required to epigentically reprogram cells to their dedifferentiated form, inducing the formation of induced-pluripotent cells, could significantly increase life span (28).”
BackgroundRapamycin, But Not Resveratrol or Simvastatin, Extends Life Span of Genetically Heterogeneous Mice
Miller, R. A., Harrison, D. E., Astle, C. M., Baur, J. A., Boyd, A. R., de Cabo, R., Fernandez, E., Flurkey, K., Javors, M. A., Nelson, J. F., et al. (2011) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glq178 · Cited by 896 · cited 1×
“Inhibition of the mammalian target of rapamycin (mTORC1) pathway is perhaps the best-validated pharmacological intervention to forestall agerelated phenotypic changes; inhibition of mTORC1 using rapamycin can extend murine life span, including in settings where the treatment is initiated relatively late in life (9,10,…”
BackgroundmTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype
Herranz, N., Gallage, S., Mellone, M., Wuestefeld, T., Klotz, S., Hanley, C. J., Raguz, S., Acosta, J. C., Innes, A. J., Banito, A., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3225 · Cited by 788 · cited 1×
“As to mechanism, treatment with rapamycin has been shown to reverse signs of senescence in stem cells (7,13,14) and decrease inflammation (8,15).”
BackgroundmTOR inhibition improves immune function in the elderly
Mannick, J. B., Del Giudice, G., Lattanzi, M., Valiante, N. M., Praestgaard, J., Huang, B., Lonetto, M. A., Maecker, H. T., Kovarik, J., Carson, S., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009892 · Cited by 786 · cited 8×
“The prior experience in the clinic, showing improvement of immune function (18), also suggests that other tissues are sensitive to rapalogs.”
BackgroundMethodSelf-citationmTOR Regulation and Therapeutic Rejuvenation of Aging Hematopoietic Stem Cells
Chen, C., Liu, Y., Liu, Y., & Zheng, P. (2009) · Science Signaling · doi:10.1126/scisignal.2000559 · Cited by 680 · cited 3×
“Rapalogs have been shown to extend life span (10,12) and forestall many of these age-related morbid phenotypes (7,8,11,26,27), including in humans (18).”
BackgroundMiller, R. A., Harrison, D. E., Astle, C. M., Fernandez, E., Flurkey, K., Han, M., Javors, M. A., Li, X., Nadon, N. L., Nelson, J. F., et al. (2014) · Aging Cell · doi:10.1111/acel.12194 · Cited by 621 · cited 2×
“Inhibition of the mammalian target of rapamycin (mTORC1) pathway is perhaps the best-validated pharmacological intervention to forestall agerelated phenotypic changes; inhibition of mTORC1 using rapamycin can extend murine life span, including in settings where the treatment is initiated relatively late in life (9,10,…”
BackgroundWilkinson, J. E., Burmeister, L., Brooks, S. V., Chan, C., Friedline, S., Harrison, D. E., Hejtmancik, J. F., Nadon, N., Strong, R., Wood, L. K., et al. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2012.00832.x · Cited by 619
Signaling pathways controlling skeletal muscle mass
Egerman, M. A., & Glass, D. J. (2014) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.857291 · Cited by 555 · cited 1×
“From a safety point of view, perhaps the relative lack of a strong effect on skeletal muscle at these doses is fortuitous, given the concern of perturbing gene expression downstream of inhibiting protein synthesis pathways, which contribute to muscle maintenance, in settings of sarcopenia (the age-related loss of skel…”
BackgroundSelf-citationTransient rapamycin treatment can increase lifespan and healthspan in middle-aged mice
Bitto, A., Ito, T. K., Pineda, V. V., LeTexier, N. J., Huang, H. Z., Sutlief, E., Tung, H., Vizzini, N., Chen, B., Smith, K., et al. (2016) · eLife · doi:10.7554/elife.16351 · Cited by 474
Farrell, A. S., & Sears, R. C. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014365 · Cited by 468
王亚周 (2015) · Institutional Research Information System University of Turin (University of Turin) · doi:10.1016/j.neuroscience · Cited by 322
Late-life rapamycin treatment reverses age-related heart dysfunction
Flynn, J. M., O'Leary, M. N., Zambataro, C. A., Academia, E. C., Presley, M. P., Garrett, B. J., Zykovich, A., Mooney, S. D., Strong, R., Rosen, C. J., et al. (2013) · Aging Cell · doi:10.1111/acel.12109 · Cited by 311 · cited 3×
“Rapalogs have been shown to extend life span (10,12) and forestall many of these age-related morbid phenotypes (7,8,11,26,27), including in humans (18).”
BackgroundInflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease
Silverstein, D. M. (2009) · Pediatric Nephrology · doi:10.1007/s00467-008-1046-0 · Cited by 300 · cited 1×
“It has been noted that an inflammatory state exists in chronic kidney disease (33) as a function of aging, a finding that was recapitulated in the present study.”
ResultReduced Expression of MYC Increases Longevity and Enhances Healthspan
Hofmann, J. W., Zhao, X., De Cecco, M., Peterson, A. L., Pagliaroli, L., Manivannan, J., Hubbard, G. B., Ikeno, Y., Zhang, Y., Feng, B., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.016 · Cited by 293 · cited 2×
“This was of particular interest for a couple of reasons: first, it was recently shown that Myc haplo-insufficient mice had prolonged lifespans, and demonstrated a downregulation of several pathways, including mTORC1 signaling (17).”
BackgroundRapamycin Extends Life and Health in C57BL/6 Mice
Zhang, Y., Bokov, A., Gelfond, J., Soto, V., Ikeno, Y., Hubbard, G., Diaz, V., Sloane, L., Maslin, K., Treaster, S., et al. (2014) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glt056 · Cited by 279 · cited 1×
“Rapalogs have been shown to extend life span (10,12) and forestall many of these age-related morbid phenotypes (7,8,11,26,27), including in humans (18).”
BackgroundStevens, L. A., Viswanathan, G., & Weiner, D. E. (2010) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2010.03.010 · Cited by 270 · cited 2×
“8% of the people aged 70 years and older (32).”
BackgroundIbebunjo, C., Chick, J. M., Kendall, T., Eash, J. K., Li, C., Zhang, Y., Vickers, C., Wu, Z., Clarke, B. A., Shi, J., et al. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01036-12 · Cited by 267 · cited 1×
“The mortality rate of our male SD rat cohorts at 24 months (2 years) is ~30% and we have previously shown that at this age rats exhibit pronounced age-related loss of muscle mass and function (sarcopenia) associated with transcriptional changes of many genes in this organ (24).”
BackgroundSelf-citationHalloran, J., Hussong, S. A., Burbank, R., Podlutskaya, N., Fischer, K. E., Sloane, L. B., Austad, S. N., Strong, R., Richardson, A., Hart, M. J., et al. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.06.054 · Cited by 221 · cited 1×
“Rapalogs have been shown to extend life span (10,12) and forestall many of these age-related morbid phenotypes (7,8,11,26,27), including in humans (18).”
BackgroundClinical strategies and animal models for developing senolytic agents
Kirkland, J. L., & Tchkonia, T. (2015) · Experimental Gerontology · doi:10.1016/j.exger.2014.10.012 · Cited by 168
Hard, G. C., & Khan, K. N. (2004) · Toxicologic Pathology · doi:10.1080/01926230490422574 · Cited by 167
Gu, Z., Tan, W., Ji, J., Feng, G., Meng, Y., Da, Z., Guo, G., Xia, Y., Zhu, X., Shi, G., et al. (2016) · Aging · doi:10.18632/aging.100925 · Cited by 131 · cited 1×
“As to mechanism, treatment with rapamycin has been shown to reverse signs of senescence in stem cells (7,13,14) and decrease inflammation (8,15).”
BackgroundO’Brown, Z. K., Van Nostrand, E. L., Higgins, J. P., & Kim, S. K. (2015) · PLOS Genetics · doi:10.1371/journal.pgen.1005734 · Cited by 90 · cited 1×
“There are many studies that demonstrate inflammatory signaling increases with age (8,30,31), and this was seen in the kidney in the current study.”
BackgroundHard, G. C., & Seely, J. C. (2005) · Toxicologic Pathology · doi:10.1080/01926230500299716 · Cited by 53 · cited 2×
“Semiquantitative histopathology scoring of hematoxylin and eosin (H&E)-stained longitudinal sections of frozen kidneys for chronic progressive nephropathy lesions (25) was performed by light microscopy according to standard methods (21,22).”
MethodChronic Progressive Nephropathy in Aging Rats
Barthold, S. W. (1979) · Toxicologic Pathology · doi:10.1177/019262337900700101 · Cited by 38 · cited 1×
“Semiquantitative histopathology scoring of hematoxylin and eosin (H&E)-stained longitudinal sections of frozen kidneys for chronic progressive nephropathy lesions (25) was performed by light microscopy according to standard methods (21,22).”
MethodTranslational strategies in aging and age-related disease
Armanios, M., de Cabo, R., Mannick, J., Partridge, L., van Deursen, J., & Villeda, S. (2015) · Nature Medicine · doi:10.1038/nm.4004 · Cited by 36
Self-citation
Cited by
Measuring biological aging in humans: a quest
Ferrucci, L., Gonzalez‐Freire, M., Fabbri, E., Simonsick, E., Tanaka, T., Moore, Z., Salimi, S., Sierra, F., & de Cabo, R. (2020) · Aging Cell · doi:10.1111/acel.13080 · Cited by 781
“Accordingly, pretreatment with rapamycin analogs that inhibit TORC1 enhances immune function and reduces infections in the elderly (Mannick et al., 2014; Shavlakadze et al., 2018).”
BackgroundAutophagy in kidney homeostasis and disease
Tang, C., Livingston, M. J., Liu, Z., & Dong, Z. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0309-2 · Cited by 496
Control of satellite cell function in muscle regeneration and its disruption in ageing
Sousa-Victor, P., García-Prat, L., & Muñoz-Cánoves, P. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00421-2 · Cited by 476
Lysosome: The metabolic signaling hub
Lamming, D. W., & Bar‐Peled, L. (2019) · Traffic · doi:10.1111/tra.12617 · Cited by 173
Shavlakadze, T., Morris, M., Fang, J., Wang, S. X., Zhu, J., Zhou, W., Tse, H. W., Mondragon-Gonzalez, R., Roma, G., & Glass, D. J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.043 · Cited by 170
Self-citation
Metadata
- Authors
- Shavlakadze, T., Zhu, J., Wang, S., Zhou, W., Morin, B., Egerman, M. A., Fan, L., Wang, Y., Iartchouk, O., Meyer, A., Valdez, R. A., Mannick, J. B., Klickstein, L. B., & Glass, D. J.
- Affiliations
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts
- Genomics Institute of the Novartis Research Foundation (US)
- Novartis Institutes for BioMedical Research (CH)
- Corresponding author
- Glass, David J
- ORCID
- Venue
- The Journals of Gerontology: Series A
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-01-03
- Volume
- 73
- Issue
- 7
- Pages
- 845-852
- ISSN
- 1079-5006 (ISSN-L)
- 1758-535X
- PMC
- PMC6001891
- OpenAlex
- W2782332875
- Cited by
- 59
- References
- 33
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 1 · 2023: 6 · 2022: 6 · 2021: 10 · 2020: 10 · 2019: 9 · 2018: 6
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journals of Gerontology Series A (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Novartis
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- mTORC1 inhibition, rapalogs, everolimus, aging, chronic progressive nephropathy, c-Myc, gene expression changes, proteasome inhibition, liver, skeletal muscle
- MeSH terms
- Everolimus, Mechanistic Target of Rapamycin Complex 1, Aging, Animals, Drug Administration Schedule, Enzyme Inhibitors, Humans, Kidney, Liver, Longevity, Male, Gene Expression, Rats, Sprague-Dawley, Muscle, Skeletal, Gene Expression Profiling, Rats, Renal Insufficiency, Chronic, HEK293 Cells, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.